Regal Investment Fund (ASX:RF1) Chief Investment Officer Phil King has taken responsibility for the firm's losses stemming from its investment in Opthea (ASX:OPT), the Australian Financial Review reported Wednesday, citing a letter to investors.
Opthea has said that its study of the combination of OPT-302 and aflibercept in patients with age-related macular degeneration failed to meet its primary endpoint, prompting it to terminate the study. It also added that there is "significant" doubt about its ability to continue as a going concern.
Regal, which held a 30% stake in Opthea, has written down the investment to zero, acknowledging the blow to investor returns across several funds, the report said.
The loss is expected to "significantly" affect the performance of Regal's long and short equity strategies for March, the report said.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.